On November 16, local time, Pfizer's US official website showed that its company has submitted an emergency use authorization (EUA) for the new crown oral drug PAXLOVID to the FDA for the treatment of patients with mild to moderate COVID-19 who are at increased risk of hospitalization or death middle.
PAXLOVID is an investigational SARS-CoV-2 protease inhibitor antiviral therapy. PF-07321332 is designed to block the activity of SARS-CoV-2-3CL protease, which is an enzyme required for coronavirus replication. Combining with low-dose ritonavir helps to slow down the metabolism or decomposition of PF-07321332, so that it stays active in the body at a higher concentration for a longer period of time to help fight the virus.
At the same time, Pfizer announced on its official website that it and the Pharmaceutical Patent Pool (MPP) have signed a license agreement for COVID-19 oral antiviral therapy candidates to expand their accessibility in low- and middle-income countries.
According to the terms of the general license agreement between Pfizer and MPP, qualified generic drug manufacturers authorized by MPP will be able to provide the drug to 95 countries, covering approximately 53% of the world's population. Including all low- and middle-income countries, as well as sub-Saharan middle- and high-income countries. In addition, it also includes countries that have transitioned from low-medium to high-medium status in the past five years.
